WuXi Biologics (Cayman) Inc

02269: XHKG (HKG)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
H@LOCK|hS<&!LOCK|!nX$CZ

Wuxi Bio Earnings: Revenue Miss Due to Lower Pricing, Offset by Robust Backlog and Project Adds

Wuxi Bio's second-half 2025 revenue grew 17% year on year to CNY 11.8 billion, driven by greater late-stage projects that command higher pricing, and a 670-basis-point expansion in operating margin.

Sponsor Center